FDA Drug Safety Communication: Seizure Risk for Multiple Sclerosis Patients Who Take Ampyra (Dalfampridine)

Why It Matters

Seizures can be life‑threatening and are linked to elevated drug levels in patients with reduced kidney function, so the FDA’s guidance forces clinicians to screen renal function and adjust use, potentially limiting Ampyra’s market and prompting broader scrutiny of neurologic drugs.

Key Takeaways

• Seizures often occur within weeks of starting Ampyra
• Risk highest in patients >50 with mild renal impairment
• FDA mandates renal function testing before and during treatment
• Missed doses must not be doubled; dosing raises seizure risk
• Ampyra contraindicated for prior seizures or CrCl ≤50 mL/min

Pulse Analysis

Ampyra (dalfampridine) was granted FDA approval in 2010 as the first oral therapy aimed at improving gait speed in multiple sclerosis (MS) patients. The drug works by blocking potassium channels, thereby enhancing neuronal conduction, but the exact mechanism in demyelinated nerves remains incompletely understood. Early clinical trials demonstrated modest gains in walking distance, leading to rapid adoption—about 46,000 prescriptions were written in the first year alone. However, post‑marketing surveillance quickly identified seizures as a serious adverse event, prompting regulatory attention.

Seizure risk with Ampyra correlates strongly with plasma concentration, which rises when renal clearance declines. The FDA’s analysis showed that most reported seizures occurred within the first week of therapy and in patients over 50, a group where age‑related glomerular filtration rate reduction is common even with normal serum creatinine. Consequently, the agency revised the label to require a baseline creatinine clearance estimate—using the Cockcroft‑Gault formula—and annual monitoring thereafter. Patients with moderate to severe impairment (CrCl ≤50 mL/min) are contraindicated, while those with mild impairment (CrCl 51‑80 mL/min) need a careful risk‑benefit assessment.

The updated safety communication forces neurologists and primary‑care providers to integrate renal function testing into routine MS care, potentially reducing Ampyra’s prescribing volume. For pharmaceutical companies, the warning highlights the importance of post‑marketing pharmacovigilance and may accelerate development of next‑generation agents with lower renal dependence. Patients now receive clearer instructions to avoid dose‑doubling after missed doses, a practice previously linked to higher seizure incidence. Overall, the FDA’s action underscores how age‑related organ decline can transform the risk profile of established therapies, prompting clinicians to balance mobility benefits against neurologic safety.